Abstract
Alzheimers disease (AD) is a progressive, degenerative disorder of the brain and the most common form of dementia among the elderly. As the population grows and lifespan is extended, the number of AD patients will continue to rise. Current clinical therapies for AD provide partial symptomatic benefits for some patients; however, none of them modify disease progression. Amyloid-β (Aβ) peptide, the major component of senile plaques in AD patients, is considered to play a crucial role in the pathogenesis of AD thereby leading to Aβ as a target for treatment. Aβ immunotherapy has been shown to induce a marked reduction in amyloid burden and an improvement in cognitive function in animal models. Although preclinical studies were successful, the initial human clinical trial of an active Aβ vaccine was halted due to the development of meningoencephalitis in ˜ 6% of the vaccinated AD patients. Some encouraging outcomes, including signs of cognitive stabilization and apparent plaque clearance, were obtained in subset of patients who generated antibody titers. These promising preliminary data support further efforts to refine Aβ immunotherapy to produce highly effective and safer active and passive vaccines for AD. Furthermore, some new human clinical trials for both active and passive Aβ immunotherapy are underway. In this review, we will provide an update of Aβ immunotherapy in animal models and in human beings, as well as discuss the possible mechanisms underlying Aβ immunotherapy for AD.
Keywords: Amyloid-β, immunotherapy, Alzheimer's disease, transgenic mice, clinical trials
CNS & Neurological Disorders - Drug Targets
Title: Amyloid-β Immunotherapy for Alzheimers Disease
Volume: 9 Issue: 2
Author(s): H.J. Fu, B. Liu, J.L. Frost and C.A. Lemere
Affiliation:
Keywords: Amyloid-β, immunotherapy, Alzheimer's disease, transgenic mice, clinical trials
Abstract: Alzheimers disease (AD) is a progressive, degenerative disorder of the brain and the most common form of dementia among the elderly. As the population grows and lifespan is extended, the number of AD patients will continue to rise. Current clinical therapies for AD provide partial symptomatic benefits for some patients; however, none of them modify disease progression. Amyloid-β (Aβ) peptide, the major component of senile plaques in AD patients, is considered to play a crucial role in the pathogenesis of AD thereby leading to Aβ as a target for treatment. Aβ immunotherapy has been shown to induce a marked reduction in amyloid burden and an improvement in cognitive function in animal models. Although preclinical studies were successful, the initial human clinical trial of an active Aβ vaccine was halted due to the development of meningoencephalitis in ˜ 6% of the vaccinated AD patients. Some encouraging outcomes, including signs of cognitive stabilization and apparent plaque clearance, were obtained in subset of patients who generated antibody titers. These promising preliminary data support further efforts to refine Aβ immunotherapy to produce highly effective and safer active and passive vaccines for AD. Furthermore, some new human clinical trials for both active and passive Aβ immunotherapy are underway. In this review, we will provide an update of Aβ immunotherapy in animal models and in human beings, as well as discuss the possible mechanisms underlying Aβ immunotherapy for AD.
Export Options
About this article
Cite this article as:
Fu H.J., Liu B., Frost J.L. and Lemere C.A., Amyloid-β Immunotherapy for Alzheimers Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (2) . https://dx.doi.org/10.2174/187152710791012017
DOI https://dx.doi.org/10.2174/187152710791012017 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Synthetic Compounds as Potential Anticryptococcal Agents
Current Organic Synthesis Crimean-Congo Hemorrhagic Fever Virus
Current Molecular Medicine Processing of Amyloid Precursor Protein as a Biochemical Link Between Atherosclerosis and Alzheimers Disease
Cardiovascular & Hematological Disorders-Drug Targets The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Current Topics in Medicinal Chemistry Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer’s Disease Pathology
Current Alzheimer Research Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue
Combinatorial Chemistry & High Throughput Screening Dynamics of T Cells Repertoire During Trypanosoma cruzi Infection and its Post-Treatment Modulation
Current Medicinal Chemistry Effective Antiviral Medicinal Plants and Biological Compounds Against Central Nervous System Infections: A Mechanistic Review
Current Drug Discovery Technologies Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Lymphocytic Choriomeningitis Virus Infection: Neglected Teratogenic Zoonosis
Current Women`s Health Reviews Searching for Disease-Modifying Drugs in AD: Can We Combine Neuropsychological Tools with Biological Markers?
CNS & Neurological Disorders - Drug Targets Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs
Infectious Disorders - Drug Targets The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Oral Administration of Thioflavin T Prevents Beta Amyloid Plaque Formation in Double Transgenic AD Mice
Current Alzheimer Research Disease Modifying Approaches for Alzheimers Pathology
Current Pharmaceutical Design Antibody Responses, Amyloid-β Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial
CNS & Neurological Disorders - Drug Targets Immunotherapy for Alzheimers Disease: Potential Problems and Possible Solutions
Current Immunology Reviews (Discontinued)